Progyny, Inc. insider trading
Every open-market purchase and sale by Progyny, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Progyny, Inc.’s insiders pay?
From October 29, 2019 to September 14, 2026, 15 insiders reported 3 open-market purchases and 35 sales not made under a pre-set plan in Progyny, Inc. Twelve months after each purchase was reported, the shares were +36.0% against the S&P 500 on average (median +36.0%), over 2 purchases with a full year of prices; 100% beat the index. After sales, the shares moved −8.6% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on December 27, 2024 into $17,402 by November 2, 2026, +35.3% a year. It held shares 100% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $12,964 (+15.2% a year), and held throughout $12,964 (+15.2%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Anevski Peter | CHIEF EXECUTIVE OFFICER | 2 | +36.0% (1) | 100% | 5 | +39.8% (5) | November 17, 2025 |
| Scott Cheryl | Director | 0 | — | — | 6 | −30.9% (5) | June 3, 2026 |
| Gordon Kevin K | Director | 0 | — | — | 5 | −50.8% (3) | September 14, 2026 |
| Livingston Mark S. | CHIEF FINANCIAL OFFICER | 0 | — | — | 5 | −18.6% (5) | December 5, 2022 |
| Bealer Jennifer | EVP, General Counsel | 0 | — | — | 2 | −1.9% (2) | June 25, 2021 |
| Bonderman David | Other | 0 | — | — | 2 | −52.6% (2) | August 9, 2023 |
| Schlanger David J | Executive Chairman | 1 | +36.0% (1) | 100% | 1 | +41.2% (1) | December 26, 2024 |
| Tpg Group Holdings (sbs) Advisors, Inc. | 10% owner | 0 | — | — | 2 | −40.0% (2) | July 8, 2021 |
| Ajmani Karin | EVP, Chief of Strategic Dev. | 0 | — | — | 1 | +41.2% (1) | October 29, 2019 |
| Clapp Geoffrey | Chief Product Officer | 0 | — | — | 1 | — | June 3, 2026 |
| Coulter James G | 10% owner | 0 | — | — | 1 | −38.9% (1) | July 6, 2021 |
| Gsk PLC | 10% owner | 0 | — | — | 1 | +90.7% (1) | May 21, 2020 |
| Payson Norman | Director | 0 | — | — | 1 | +41.2% (1) | October 29, 2019 |
| Seidenberg Beth C | Director | 0 | — | — | 1 | −20.3% (1) | April 19, 2021 |
| Winkelried Jon | 10% owner | 0 | — | — | 1 | −32.4% (1) | November 9, 2022 |
When several insiders traded Progyny, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Progyny, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged +17.8% against the index. After 3 selling crowds, +6.5%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| June 30, 2026 | 3 selling | −16.6% | not yet | not yet |
| December 31, 2024 | 2 buying | +42.4% | +17.8% | +35.8% |
| December 30, 2022 | 3 selling | −6.2% | +4.7% | −8.1% |
| June 30, 2021 | 5 selling | −8.0% | −23.9% | −40.1% |
| October 31, 2019 | 5 selling | +54.8% | +38.6% | +38.6% |